⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RPTX News
Repare Therapeutics Inc. Common Shares
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
globenewswire.com
RPTX
AMRX
TREOS Bio Appoints Sunjeet Sawhney as Chief Executive Officer
globenewswire.com
RPTX
NVS
Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals
globenewswire.com
RPTX
ARVN
RGNX
Reveal Expands Private Deployment Investment by 50% as Enterprise Demand Surges
businesswire.com
RPTX
CSL
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
businesswire.com
RPTX
Grocery TV Adds to Leadership Team as In-Store Retail Media Accelerates
prnewswire.com
WMT
CRTO
VOLT
RPTX
Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica
globenewswire.com
PFE
IQV
ORCL
MED
RPTX
ICLR
AZN
JNJ
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
businesswire.com
RPTX
Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
prnewswire.com
EDIT
NTLA
RPTX
NVS
GILD
BMY
VRTX
CRL
OCGN